Andrzej Rostek
- PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints.
- The biotech company said the drug failed to demonstrate statistical significance in the slowing of disease